Fig. 1 · Structure

Documents & Downloads

(+)-Alliin

Cat. No. A12016 CAS 556-27-4
Alliin is a cysteine sulfoxide constituent of garlic that is converted by alliinase to allicin, which imparts its pungent aroma and flavor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

(+)-Alliin Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of (+)-Alliin from 3 published references. In vitro models include 3T3-L1 differentiated adipocytes; ox-LDL-injured HUVECs. In vivo models include DIO mice.

(+)-Alliin In Vitro Studies

In differentiated 3T3-L1 adipocytes, (+)-Alliin pretreatment followed by exposure to alliin plus LPS was associated with modified gene expression compared with LPS alone. In ox-LDL-injured HUVECs, treatment with (+)-Alliin yielded 33 up-regulated proteins and 17 down-regulated proteins relative to the injured control. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Gene expression after inflammatory stimulation in differentiated adipocytes

Cell-based study · 3T3-L1 differentiated adipocytes [1]

Differentiated 3T3-L1 adipocytes were pretreated with (+)-Alliin and then exposed to LPS with alliin. Microarray analysis identified modified gene expression in the alliin plus LPS condition compared with LPS alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
microarray analysisgene expression 2,108 genes[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 mM
Exposure duration
On day 8 after differentiation, the cells were pretreated during a 24 h period with a medium containing 0.1 mM alliin (Sigma Chemical Co.). Cells were then incubated with the same medium along with LPS (100 ng/mL) for 1 h before being harvested.
Method
a medium containing 0.1 mM alliin
Co-treatment
Other interventions in this design: LPS 100 ng/mL; dexamethasone 0.25 μM; 3-isobutyl-1-methylxanthine 0.5 mM; insulin 5 μg/mL. Compound effect isolated by the comparison: LPS versus alliin + LPS.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: (+)-Alliin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Cell Culture (S3); 2. Materials and Methods > 2.2. T3-L1 Cell Treatment (S5, S6); 3. Results > 3.3. Gene Expression Profile of Alliin Pretreated 3T3-L1 Cells after LPS Stimulus Is Consistent with a Shift in Cell Response to Inflammatory Stimulus and Reveals Alliin Action on Adipocyte Physiology (S62, S63, S68, S70)

microarray analysis: microarray analysis; comparator: LPS — 3. Results > 3.3. Gene Expression Profile of Alliin Pretreated 3T3-L1 Cells after LPS Stimulus Is Consistent with a Shift in Cell Response to Inflammatory Stimulus and Reveals Alliin Action on Adipocyte Physiology (S62, S70)

Differential protein expression in injured endothelial cells

Cell-based study · ox-LDL-injured HUVECs [2]

Ox-LDL-injured HUVECs were treated with (+)-Alliin solution. Compared with the ox-LDL-injured control, 33 proteins were up-regulated and 17 proteins were down-regulated in the Alliin/Mod group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
differential protein expressiondifferential protein expression 33 proteins were up-regulated and 17 proteins were down-regulated[2]

Literature-Reported Treatment Conditions

Treatment concentration
25 mg/L
Exposure duration
80 mg/L ox-LDL (2 ml) for 24 h followed by treatment with 25 mg/L alliin solution (2 ml) for 24 h
Method
treatment with 25 mg/L alliin solution (2 ml)
Co-treatment
Other interventions in this design: ox-LDL 80 mg/L. Compound effect isolated by the comparison: Alliin/Mod.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: (+)-Alliin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell sample Preparation and protein extraction (S33); Results > Differentially expressed proteins statistics (S83, S86, S88)

differential protein expression: differential protein expression; comparator: 80 mg/L ox-LDL-injured HUVECs (Mod) — Results > Differentially expressed proteins statistics (S83, S86)

(+)-Alliin In Vivo Studies

In DIO mice, (+)-Alliin administered in drinking water modified intestinal microbiota composition, which differed significantly from drinking-water controls. In the glucose study, DIO mice receiving (+)-Alliin in drinking water had significantly lower glucose levels following glucose injection than control mice. [3]

Alliin Modifies Intestinal Microbiota in DIO Mice

Animal study · DIO mice [3]

DIO mice received (+)-Alliin at 0.1 mg/ml in drinking water for another 8 weeks. Intestinal microbiota composition differed significantly between alliin-treated mice and drinking-water controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intestinal taxonomic compositionReported result Water soluble alliin (0.1 mg/ml) was added to the drinking water. The mice were given either the alliin containing water or drinking water only for another 8 weeks. Alliin modified the intestinal microbiota, which was significantly different between the alliin treated mice and the control (ANOSIM = 0.0008).[3]

Conditions shared by the study groups

Route
added to the drinking water
Treatment course
another 8 weeks
Vehicle
drinking water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
(+)-Alliin 0.1 mg/mldrinking water onlyWater soluble alliin (0.1 mg/ml) was added to the drinking water. The mice were given either the alliin containing water or drinking water only for another 8 weeks. Alliin modified the intestinal microbiota, which was significantly different between the alliin treated mice and the control (ANOSIM = 0.0008).[3]
(+)-Alliin 0.1 mg/ml
Model: DIO mice
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: (+)-Alliin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Alliin modifies intestinal microbiota of DIO mice (S32, S36); Methods > Animals (S43, S44, S45)

intestinal taxonomic composition: intestinal taxonomic composition; comparator: drinking water only — Results > Alliin modifies intestinal microbiota of DIO mice (S32, S36); Methods > Animals (S44, S45)

(+)-Alliin 0.1 mg/ml · Results > Alliin modifies intestinal microbiota of DIO mice (S32); Methods > Animals (S44, S45)

Glucose levels in DIO mice after glucose injection

Animal study · DIO mice [3]

DIO mice received (+)-Alliin added to drinking water. Glucose levels were significantly lower in treated mice than in control mice at the reported times after glucose injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Glucose levelReported result Glucose level in alliin treated mice was significantly lower than that of the control mice at 30, 45 and 60 min post injection of glucose[3]

Conditions shared by the study groups

Route
added to the drinking water
Treatment course
another 8 weeks; at the 6th week
Vehicle
drinking water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
(+)-Alliin 0.1 mg/mlcontrol miceGlucose level in alliin treated mice was significantly lower than that of the control mice at 30, 45 and 60 min post injection of glucose[3]
(+)-Alliin 0.1 mg/ml
Model: DIO mice
Methods and source locations

Compound reported in the paper: (+)-Alliin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Alliin maintains glucose homeostasis and improves insulin sensitivity (S3, S4); Methods > Animals (S43, S44, S45); Methods > Glucose tolerance test and insulin tolerance test (S48)

Glucose level: Glucose level; comparator: control mice — Results > Alliin maintains glucose homeostasis and improves insulin sensitivity (S4)

(+)-Alliin 0.1 mg/ml · Results > Alliin maintains glucose homeostasis and improves insulin sensitivity (S4); Methods > Animals (S44, S45); Methods > Glucose tolerance test and insulin tolerance test (S48)

Specifications

Manufacturer Adooq Bioscience
CAS Number 556-27-4
Formula C6H11NO3S
Molecular Weight 177.22
SMILES
C=CC[S@](=O)C[C@@H](C(=O)O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 3 mg/mL (16.92 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

(+)-Alliin Research References

  1. [1] Quintero-Fabián S, Ortuño-Sahagún D, Vázquez-Carrera M, et al. Alliin, a garlic (Allium sativum) compound, prevents LPS-induced inflammation in 3T3-L1 adipocytes. Mediators Inflamm (2013). PMID: 24453416 DOI: 10.1155/2013/381815 Source material
  2. [2] Tang YY, Lv D. Quantitative proteomic analysis of the protective effect exerted by alliin on ox-LDL-injured HUVECs. Sci Rep (2025). PMID: 40379781 DOI: 10.1038/s41598-025-01677-w Source material
  3. [3] Zhai B, Zhang C, Sheng Y, et al. Hypoglycemic and hypolipidemic effect of S-allyl-cysteine sulfoxide (alliin) in DIO mice. Sci Rep (2018). PMID: 29476144 DOI: 10.1038/s41598-018-21421-x Source material

Added to your cart

View Cart Checkout
Loading...